Creative Biolabs, a biotechnology research service provider, has announced the expansion of its complement assay service portfolio, aiming to support the development of next-generation complement therapeutics. This move addresses the growing demand for specialized functional assays in complement-targeted drug discovery, where researchers often struggle with complex pathways and the need for reproducible data.
The expanded services offer customizable solutions for early discovery and preclinical evaluation, enabling scientists to investigate complement activation mechanisms and assess candidate activity. Among the offerings, the C3b deposition assay measures a critical marker in the complement cascade, providing quantitative data for characterizing complement-targeting antibodies and proteins. Additionally, the hemolytic inhibition assay evaluates the ability of test candidates to inhibit complement-mediated cell lysis, facilitating comparisons of inhibitory activity under defined conditions.
Furthermore, Creative Biolabs' individual components activity tests allow detailed analysis of specific complement proteins, supporting mechanistic studies and pathway investigations. These capabilities help researchers generate actionable data for candidate selection and optimization, reducing research complexity and improving development efficiency.
The expansion reflects Creative Biolabs' commitment to complement-focused research, combining scientific expertise with customized assay solutions. Researchers interested in these services can explore the offerings at Creative Biolabs Complement Therapeutics.
